Home » Antibodies by Design, JPT Announce Cooperation Agreement
Antibodies by Design, JPT Announce Cooperation Agreement
April 18, 2005
Antibodies by Design, a division of MorphoSys, and JPT Peptide Technologies, a wholly owned subsidiary of Jerini, announced the start of a co-marketing agreement between the two specialist companies. Within the scope of this agreement the parties agree to co-market the rapid generation of monoclonal antibodies by Antibodies by Design and the complementary peptide-based services and products from JPT. Each partner will offer the services of the other to its customers throughout the worldwide market, with exception of Japan.
Business Wire
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct